TWI700296B - 失智症治療劑或預防劑 - Google Patents

失智症治療劑或預防劑 Download PDF

Info

Publication number
TWI700296B
TWI700296B TW102119176A TW102119176A TWI700296B TW I700296 B TWI700296 B TW I700296B TW 102119176 A TW102119176 A TW 102119176A TW 102119176 A TW102119176 A TW 102119176A TW I700296 B TWI700296 B TW I700296B
Authority
TW
Taiwan
Prior art keywords
sequence
antibody
tau
seq
cdr
Prior art date
Application number
TW102119176A
Other languages
English (en)
Chinese (zh)
Other versions
TW201410705A (zh
Inventor
森啓
富山貴美
松本洋一
江口広志
九里裕一
Original Assignee
公立大學法人大阪市立大學
日商帝人製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 公立大學法人大阪市立大學, 日商帝人製藥股份有限公司 filed Critical 公立大學法人大阪市立大學
Publication of TW201410705A publication Critical patent/TW201410705A/zh
Application granted granted Critical
Publication of TWI700296B publication Critical patent/TWI700296B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
TW102119176A 2012-05-31 2013-05-30 失智症治療劑或預防劑 TWI700296B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012124336 2012-05-31
JP2012-124336 2012-05-31

Publications (2)

Publication Number Publication Date
TW201410705A TW201410705A (zh) 2014-03-16
TWI700296B true TWI700296B (zh) 2020-08-01

Family

ID=49673425

Family Applications (2)

Application Number Title Priority Date Filing Date
TW102119176A TWI700296B (zh) 2012-05-31 2013-05-30 失智症治療劑或預防劑
TW109121902A TWI777183B (zh) 2012-05-31 2013-05-30 失智症治療劑或預防劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109121902A TWI777183B (zh) 2012-05-31 2013-05-30 失智症治療劑或預防劑

Country Status (30)

Country Link
US (3) US20150183854A1 (enExample)
EP (2) EP2857039B1 (enExample)
JP (3) JP5971659B2 (enExample)
KR (2) KR102133610B1 (enExample)
CN (1) CN104602708B (enExample)
AR (1) AR091218A1 (enExample)
AU (2) AU2013268364B2 (enExample)
BR (1) BR112014029566A2 (enExample)
CA (1) CA2875205C (enExample)
CY (1) CY1122530T1 (enExample)
DK (1) DK2857039T3 (enExample)
ES (2) ES2763361T3 (enExample)
HR (1) HRP20192267T1 (enExample)
HU (1) HUE046919T2 (enExample)
IL (1) IL235899B (enExample)
LT (1) LT2857039T (enExample)
ME (1) ME03587B (enExample)
MX (1) MX361128B (enExample)
MY (1) MY172458A (enExample)
NZ (1) NZ630536A (enExample)
PH (1) PH12014502669B1 (enExample)
PL (1) PL2857039T3 (enExample)
PT (1) PT2857039T (enExample)
RS (1) RS59802B1 (enExample)
RU (1) RU2657438C2 (enExample)
SG (2) SG10201805410XA (enExample)
SI (1) SI2857039T1 (enExample)
TW (2) TWI700296B (enExample)
WO (1) WO2013180238A1 (enExample)
ZA (1) ZA201409186B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
EP2709728B1 (en) * 2011-05-20 2019-01-23 Oligomerix, Inc. Tau protease methods of use
BR112014029566A2 (pt) * 2012-05-31 2017-07-25 Univ Osaka City agente terapêutico ou agente profilático para desordens cognitivas, anticorpo monoclonal, anticorpo para proteína tau fosforilada, e, peptídeo
JP6345655B2 (ja) 2012-07-03 2018-06-20 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN109791149A (zh) * 2016-09-30 2019-05-21 豪夫迈·罗氏有限公司 用于功能分析多特异性分子的基于spr的双重结合测定法
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
BR112019022789A2 (pt) 2017-05-30 2020-06-09 Teijin Pharma Ltd anticorpo do receptor de anti-igf-i ou fragmento do mesmo ou um derivado do mesmo, molécula de ácido nucleico, vetor de clonagem ou vetor de expressão, célula recombinante, processo de produção de um anticorpo do receptor de anti-igf-i ou fragmento do mesmo ou um derivado do mesmo, composição farmacêutica, medicamento, método para cultivar células derivadas de vertebrados in vitro, e, animal transgênico.
MA50629A (fr) 2017-10-02 2021-03-31 Merck Sharp & Dohme Composés monobactames de chromane pour le traitement d'infections bactériennes
NZ762251A (en) 2017-10-16 2025-12-19 Eisai R&D Man Co Ltd Anti-tau antibodies and uses thereof
US11667707B2 (en) 2018-04-06 2023-06-06 Teijin Pharma Limited SPNS2 neutralizing antibody
CN112469827B (zh) * 2018-07-04 2024-05-24 学校法人爱知医科大学 控制Tau的剪接的反义寡核苷酸及其用途
CN110028583B (zh) * 2019-05-07 2020-09-11 温州医科大学 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
JP7429404B2 (ja) * 2019-08-06 2024-02-08 慶應義塾 タウ関連疾患モデルの製造方法
EP4040153A4 (en) 2019-09-30 2023-07-26 Nipro Corporation PROCEDURE FOR DETECTING TAU PROTEIN USING A BLOOD SAMPLE AS SAMPLE
JP2023518281A (ja) 2020-03-19 2023-04-28 ヴァスキュラー バイオサイエンスィズ コロナウイルス生存率改善のためのｃａｒペプチド
EP4171633A1 (en) * 2020-06-25 2023-05-03 Merck Sharp & Dohme LLC High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO2010144711A2 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587390B2 (ja) 1975-03-11 1983-02-09 ツキシマキカイ カブシキガイシヤ ア−クヨウセツホウホウ
JP3587390B2 (ja) 1994-03-17 2004-11-10 タカラバイオ株式会社 リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
CA2655634A1 (en) * 2006-06-16 2007-12-27 Envivo Pharmaceuticals, Inc. Transgenic flies expressing tau and amyloid precursor fragment
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US8703137B2 (en) * 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
TR201102696U (tr) * 2011-05-27 2011-06-21 Turhal Sal�H Bağlantısız hareketli ürün reklam standı.
BR112014029566A2 (pt) * 2012-05-31 2017-07-25 Univ Osaka City agente terapêutico ou agente profilático para desordens cognitivas, anticorpo monoclonal, anticorpo para proteína tau fosforilada, e, peptídeo
JP2018139530A (ja) * 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO2010144711A2 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins

Also Published As

Publication number Publication date
AU2018200413A1 (en) 2018-02-08
AU2013268364B2 (en) 2018-02-08
ES2973070T3 (es) 2024-06-18
JP6620829B2 (ja) 2019-12-18
TW201410705A (zh) 2014-03-16
HUE046919T2 (hu) 2020-04-28
SG10201805410XA (en) 2018-08-30
SI2857039T1 (sl) 2020-03-31
EP3662931A1 (en) 2020-06-10
WO2013180238A1 (ja) 2013-12-05
RU2014153099A (ru) 2016-07-20
EP2857039A4 (en) 2015-08-26
MX361128B (es) 2018-11-28
US20200148753A1 (en) 2020-05-14
TWI777183B (zh) 2022-09-11
HRP20192267T1 (hr) 2020-03-20
EP2857039A1 (en) 2015-04-08
MX2014014187A (es) 2015-06-04
RS59802B1 (sr) 2020-02-28
IL235899B (en) 2019-03-31
KR102208283B1 (ko) 2021-01-26
KR20200029619A (ko) 2020-03-18
CY1122530T1 (el) 2021-01-27
DK2857039T3 (da) 2019-12-16
JPWO2013180238A1 (ja) 2016-01-21
LT2857039T (lt) 2020-03-10
ZA201409186B (en) 2015-12-23
AU2013268364A1 (en) 2014-12-18
PT2857039T (pt) 2020-01-07
AU2018200413B2 (en) 2019-10-17
CA2875205C (en) 2021-07-20
EP2857039B1 (en) 2019-11-20
TW202041532A (zh) 2020-11-16
HK1210031A1 (en) 2016-04-15
JP2016147902A (ja) 2016-08-18
JP5971659B2 (ja) 2016-08-17
KR20150027098A (ko) 2015-03-11
PH12014502669A1 (en) 2015-02-02
PH12014502669B1 (en) 2020-02-19
RU2657438C2 (ru) 2018-06-13
CA2875205A1 (en) 2013-12-05
CN104602708B (zh) 2021-11-30
JP2018111716A (ja) 2018-07-19
SG11201407878VA (en) 2015-01-29
IL235899A0 (en) 2015-01-29
AR091218A1 (es) 2015-01-21
BR112014029566A2 (pt) 2017-07-25
CN104602708A (zh) 2015-05-06
US20150183854A1 (en) 2015-07-02
KR102133610B1 (ko) 2020-07-14
JP6406678B2 (ja) 2018-10-17
ME03587B (me) 2020-07-20
US20220340646A1 (en) 2022-10-27
MY172458A (en) 2019-11-26
ES2763361T3 (es) 2020-05-28
NZ630536A (en) 2017-03-31
EP3662931B1 (en) 2023-12-06
PL2857039T3 (pl) 2020-05-18

Similar Documents

Publication Publication Date Title
TWI777183B (zh) 失智症治療劑或預防劑
CN103179981B (zh) 安全和功能性的人源化抗β‑淀粉样蛋白抗体
ES2766762T3 (es) Inmunoterapia contra Tau
KR102533675B1 (ko) 타우 인식 항체
TW201716436A (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
TW201809004A (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TW202400643A (zh) 神經退化性疾病之治療劑
CA3128420A1 (en) Humanized anti-a.beta. monoclonal antibody and use thereof
HK40031828B (en) Therapeutic agent or prophylactic agent for dementia
HK40031828A (en) Therapeutic agent or prophylactic agent for dementia
HK1210031B (zh) 痴呆症治疗药或预防药
HK40116870A (zh) 识别sortilin的抗体
HK1185797A (en) Safe and functional humanized antibodies